Skip to main content

Market Overview

The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings

The Week Ahead In Biotech March 7-13: Conference Presentations And More Earnings

Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA rulings and clinical readouts.

Morphic Holding Inc (NASDAQ: MORF) was among the biggest gainers of the week after the company reported a positive early-stage readout in inflammatory bowel disease patients.

M&A momentum continued, as Amgen Inc. (AMGN) announced a deal to buy Five Prime Therapeutics, Inc. (NASDAQ: FPRX) in an $1.9-billion all-cash deal.

Here are the key catalysts for the unfolding week:


Chardan's 3rd Annual Microbiome Medicines Summit: March 8

H.C. Wainwright Global Life Sciences Conference: March 9-11

Barclays Global Healthcare Conference: March 9-11

15th International Conference on Alzheimer's and Parkinson's disease: March 9-14

Clinical Readouts

Prothena Corporation plc (NASDAQ: PRTA) will present at the Alzheimer's and Parkinson's disease conference new preclinical data on a treatment for Alzheimer's disease. The treatment targets an anti-tau antibody, which is thought to play a role in the disease. The company says targeting a certain antibody called a novel epitope with PRX005 has shown superior results. The presentation is scheduled for Thursday, March 11, between 7:30 a.m. and 7:45 a.m.



Minerva Neurosciences, Inc. (NASDAQ: NERV) (before the market open)
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) (after the close)
Castle Biosciences, Inc. (NASDAQ: CSTL) (after the close)
SI-BONE, Inc. (NASDAQ: SIBN) (after the close)
Avadel Pharmaceuticals plc (NASDAQ: AVDL) (after the close)

Related Link: Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates


Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (before the market open)
Trevena, Inc. (NASDAQ: TRVN) (before the market open)
InspireMD, Inc. (NYSE: NSPR) (before the market open)
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) (before the market open)
DarioHealth Corp. (NASDAQ: DRIO) (before the market open)
Gamida Cell Ltd. (NASDAQ: GMDA) (before the market open)
Evelo Biosciences, Inc. (NASDAQ: EVLO) (before the market open)
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (before the market open)
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (after the close)
Brickell Biotech, Inc. (NASDAQ: BBI) (after the close)
Cytosorbents Corporation (NASDAQ: CTSO) (after the close)
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) (after the close)
MiMedx Group, Inc. (NASDAQ: MDXG) (after the close)
Inari Medical, Inc. (NASDAQ: NARI) (after the close)
Lyra Therapeutics, Inc. (NASDAQ: LYRA) (after the close)


Bio-Path Holdings, Inc. (NASDAQ: BPTH) (before the market open)
Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open)
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) (before the market open)
Clearside Biomedical, Inc. (NASDAQ: CLSD) (after the close)
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) (after the close)
Five Prime Therapeutics (NASDAQ: FPRX) (after the close)
Flexion Therapeutics, Inc. (NASDAQ: FLXN) (after the close)
Harpoon Therapeutics, Inc. (NASDAQ: HARP) (after the close)
Lantern Pharma Inc. (NASDAQ: LTRN) (after the close)
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (after the close)
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (after the close)
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) (after the close)
OrthoPediatrics Corp. (NASDAQ: KIDS) (after the close)


Burning Rock Biotech Limited (NASDAQ: BNR) (before the market open)
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) (before the market open)
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (before the market open)
Achieve Life Sciences, Inc. (NASDAQ: ACHV) (after the close)
Capricor Therapeutics, Inc. (NASDAQ: CAPR) (after the close)
Lineage Cell Therapeutics, Inc. (NYSE: LCTX) (after the close)
Geron Corporation (NASDAQ: GERN) (after the close)
Chembio Diagnostics, Inc. (NASDAQ: CEMI) (after the close)
Ocular Therapeutix, Inc. (NASDAQ: OCUL) (after the close)
Nabriva Therapeutics plc (NASDAQ: NBRV) (after the close)

Related Link: Johnson & Johnson Secures Emergency Authorization For Its Single-Shot COVID-19 Vaccine


Related Articles (IBB)

View Comments and Join the Discussion!

Posted-In: pharmaceuticalsBiotech Earnings News Penny Stocks Small Cap FDA Top Stories Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at